ArticleShock (Augusta, Ga.)2026
The Efficacy of Whole Blood Exchange-Lymphoplasmapheresis Combined with Transfusion in Sepsis with Anemia.
Article in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis progression is driven by a dysregulated immune response and persistent leukocyte activation. Inflammation-induced hemolysis also places septic patients at high risk for anemia. Whole blood exchange has shown efficacy in severe autoimmune hemolytic anemia. Consequently, whole blood exchange-lymphoplasmapheresis combined with transfusion (WLCT) is hypothesized as a potential adjunctive therapy for sepsis complicated by anemia.
methodThis retrospective study analyzed data from 219 anemic septic patients (49 WLCT vs. 156 conventional therapy) treated between January 1, 2020, and September 30, 2023. After 1:2 propensity score matching, 38 WLCT patients were compared with 76 conventional patients. Associations between WLCT and clinical outcomes were assessed using regression analyses, with robustness verified by sensitivity analyses. A generalized additive mixed model was used to evaluate the trends in sequential organ failure assessment scores, vital signs, and laboratory indexes in two groups.
resultsPostmatching, WLCT was significantly associated with decreased risks of in-hospital mortality (26.32% vs. 48.68%, odds ratio: 0.38, 95% confidence interval: 0.16-0.88, P = 0.024) and incidence of liver failure (16.13% vs. 41.27%, odds ratio: 0.27, 95% confidence interval: 0.09-0.81, P = 0.019). Sensitivity analysis consistently supported these findings. Compared with conventional group, WLCT group demonstrated significant decreases over time in sequential organ failure assessment scores, activated partial thromboplastin time, bilirubin levels, alongside increased in mean arterial pressure, oxygen partial pressure, hemoglobin, red blood cell count, and plasminogen levels. Compared with pre-WLCT, levels of interleukin-6 (18.81 ± 22.63 vs. 116.86 ± 277.53 pg/mL, P = 0.041), C-reactive protein (37.90 ± 41.30 vs. 72.77 ± 65.59 mg/L, P = 0.020), and erythrocyte sedimentation rate (18.46 ± 22.97 vs. 50.44 ± 45.79 mm/h, P = 0.048) were significantly lower post-WLCT. After treatment, the WLCT group demonstrated significantly lower CD3+ T lymphocytes % (53.63 ± 16.31 vs. 66.14 ± 14.94, P = 0.041) and CD3+CD4+ T lymphocytes % (28.08 ± 8.90 vs. 39.18 ± 10.70, P = 0.004), but higher CD19+ B lymphocytes % (36.09 ± 18.06 vs. 19.23 ± 12.30, P = 0.007) compared with the conventional group.
conclusionsThis study evaluated the impact of WLCT therapy on mortality and other clinical outcomes in sepsis with anemia. WLCT might be an effective adjunctive treatment for managing sepsis with anemia, which was significantly associated with reduced mortality. Furthermore, WLCT might exhibit the potential to ameliorate outcomes by improving organ function, coagulation, anemia, and inflammatory status. Our study provides a potential treatment option for sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.